Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$102.94 USD
+2.62 (2.61%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $102.94 0.00 (0.00%) 4:28 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$102.94 USD
+2.62 (2.61%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $102.94 0.00 (0.00%) 4:28 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Insmed (INSM) Wins FDA Nod for Lung Disease Drug Arikayce
by Zacks Equity Research
Insmed's (INSM) lung infection drug Arikayce gains an accelerated approval from the FDA for the treatment of lung disease caused by mycobacterium avium complex (MAC).
Ultragenyx Reports Top-line Data From Gene Therapy Candidate
by Zacks Equity Research
Ultragenyx (RARE) reports encouraging top-line data from two cohorts of the study evaluating its adeno-associated virus ("AAV") gene therapy candidate -- DTX301.
3 Biotech Stocks With Rising Estimates in the Past Month
by Zacks Equity Research
The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.
Amarin's Stock Soars as Fish Oil Drug Lowers Heart Risks
by Zacks Equity Research
Amarin (AMRN) shares soar on positive results from a cardiovascular outcomes study on Vascepa.
AMAG In-Licenses Global Rights to Orphan Drug Candidate
by Zacks Equity Research
AMAG acquires global rights to develop/market DIF from Velo Bio to boost its maternal health portfolio. The candidate is under assessment for treating severe preeclampsia in pregnant women.
Time to Focus on Ligand Pharmaceuticals (LGND) for Strong Earnings Growth Potential
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Verastem Out-Licenses China Rights to Cancer Drug Copiktra
by Zacks Equity Research
Verastem (VSTM) out-licenses rights to develop/commercialize its newly approved cancer drug Copiktra to the Chinese entity, CSPC Pharmaceutical.
Alexion's Soliris Successful in Phase III Study for NMOSD
by Zacks Equity Research
Alexion's (ALXN) efforts to expand lead blockbuster drug Soliris' label gets a boost as the phase III study on the drug for the indication of NMSOD was successful.
Arena (ARNA) Posts Favorable Top-Line Data on Pain Candidate
by Zacks Equity Research
Arena (ARNA) releases initial optimistic outcomes from a phase IIa study on its pipeline candidate olorinab for treating abdominal pain associated with Crohn's disease.
FDA Lifts Clinical Hold on Epizyme's Lead Candidate's Study
by Zacks Equity Research
The FDA lifts partial clinical hold on Epizyme's lead pipeline candidate, tazemetostat's study.
FDA Lifts Clinical Hold on Sarepta's DMD Gene Therapy Program
by Zacks Equity Research
The FDA has lifted clinical hold on Sarepta's (SRPT) clinical study evaluating the Duchenne muscular dystrophy micro-dystrophin gene therapy program. The clinical hold was placed in July by the FDA.
Exelixis, Ipsen Receive Positive CHMP Opinion for Cabometyx
by Zacks Equity Research
Exelixis, Inc. (EXEL) and partner Ipsen get a positive opinion from the CHMP for Cabometyx tablets as a monotherapy for the second-line treatment of hepatocellular carcinoma in adults.
CHMP Reconfirms Negative Opinion for Sarepta's Exondys
by Zacks Equity Research
The CHMP re-confirmed the negative opinion for Sarepta's (SRPT) Exondys, which is developed to treat individuals who have a specific type of Duchenne muscular dystrophy.
FDA Confirms Positive Safety Profile of Acadia's Nuplazid
by Zacks Equity Research
Acadia's shares soar more than 20% as the FDA issues a statement reaffirming the positive benefit-risk profile of Nuplazid for patients with Parkinson's disease psychosis.
Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (LGND) Outperforming Other Medical Stocks This Year?
Ultragenyx's Shares Surge More Than 80% in the Year So Far
by Zacks Equity Research
Ultragenyx's (RARE) share price has increased by about 85.2% year to date based on some positive developments for the product candidates of the company.
Progenics Pharma's Stock Down on Dismal Phase III Study Data
by Zacks Equity Research
Progenics Pharmaceuticals' (PGNX) shares down on disappointing results from phase III study evaluating imaging agent, 1404, for prostate cancer detection.
Dr. Reddy's (RDY) Presence in Generics Market Remains Strong
by Zacks Equity Research
Dr. Reddy's has a strong hold in the generics market. New product launches, especially complex generics, are likely to drive the generics business at regular intervals.
Zacks.com highlights: Attunity, Helix Energy Solutions Group, Ligand Pharmaceuticals, Turtle Beach and SVB Financial Group
by Zacks Equity Research
Zacks.com highlights: Attunity, Helix Energy Solutions Group, Ligand Pharmaceuticals, Turtle Beach and SVB Financial Group
Enhance Your Gains With These 5 Best Profitable Stocks
by Zacks Equity Research
The best accounting tool to understand a company's profitability position is ratio analysis.
Cytori's Chemotherapy Candidate Gets Orphan Drug Status
by Zacks Equity Research
Cytori Therapeutics' (CYTX) chemotherapy candidate, ATI-1123, gets orphan drug status from the FDA for small cell lung cancer.
Gilead Inks Gene Editing Collaboration Deal for HBV Infection
by Zacks Equity Research
Gilead (GILD) enters into a strategic collaboration with Precision BioSciences for developing therapies aimed at eliminating hepatitis B virus by using the latter's gene editing platform ARCUS.
Endocyte Announces FDA's Acceptance of Trial Endpoint Change
by Zacks Equity Research
177Lu-PSMA-617, a prostate specific membrane antigen-targeted radioligand therapy, is Endocyte's (ECYT) lead program. It is being evaluated in a phase III study for mCRPC for PSMA-positive patients
Alkermes Expands Study to Evaluate ALKS 4230-Keytruda Combo
by Zacks Equity Research
Alkermes expands a phase I study to evaluate its immuno-oncology candidate, ALKS 4230, in combination with Keytruda in patients with advanced solid tumors.
Perrigo's OTC Version of Diarrhea Drug Imodium Gets FDA Nod
by Zacks Equity Research
Perrigo (PRGO) announces approval of over-the-counter equivalent of Imodium Multi-Symptom Relief tablet in the United States.